These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32911706)

  • 1. Development and Technical Validation of an Immunoassay for the Detection of APP
    Klafki HW; Rieper P; Matzen A; Zampar S; Wirths O; Vogelgsang J; Osterloh D; Rohdenburg L; Oberstein TJ; Jahn O; Beyer I; Lachmann I; Knölker HJ; Wiltfang J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplex immunoassay measurement of amyloid-β
    Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
    Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.
    Klafki HW; Hafermann H; Bauer C; Haussmann U; Kraus I; Schuchhardt J; Muck S; Scherbaum N; Wiltfang J
    J Alzheimers Dis; 2016 Sep; 54(2):691-705. PubMed ID: 27567847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
    Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR
    Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems.
    Jensen M; Hartmann T; Engvall B; Wang R; Uljon SN; Sennvik K; Näslund J; Muehlhauser F; Nordstedt C; Beyreuther K; Lannfelt L
    Mol Med; 2000 Apr; 6(4):291-302. PubMed ID: 10949910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of β-amyloid peptide (1-16) and amyloid precursor protein (APP770) using spectroscopic ellipsometry and QCM techniques: a step forward towards Alzheimers disease diagnostics.
    Mustafa MK; Nabok A; Parkinson D; Tothill IE; Salam F; Tsargorodskaya A
    Biosens Bioelectron; 2010 Dec; 26(4):1332-6. PubMed ID: 20692146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma.
    Vogelgsang J; Wiltfang J; Klafki HW
    Methods Mol Biol; 2018; 1750():111-124. PubMed ID: 29512068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for β-amyloid (1-40) and (1-42) in plasma samples.
    Yamashita K; Watanabe S; Ishiki K; Miura M; Irino Y; Kubo T; Matsui J; Hagino K; Iwanaga S; Yoshida T
    Biochem Biophys Res Commun; 2021 Oct; 576():22-26. PubMed ID: 34478915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
    J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.
    Bogstedt A; Groves M; Tan K; Narwal R; McFarlane M; Höglund K
    J Alzheimers Dis; 2015; 46(4):1091-101. PubMed ID: 26402635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease.
    Thijssen EH; Verberk IMW; Vanbrabant J; Koelewijn A; Heijst H; Scheltens P; van der Flier W; Vanderstichele H; Stoops E; Teunissen CE
    Sci Rep; 2021 May; 11(1):9736. PubMed ID: 33958661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.
    Kawarabayashi T; Younkin LH; Saido TC; Shoji M; Ashe KH; Younkin SG
    J Neurosci; 2001 Jan; 21(2):372-81. PubMed ID: 11160418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Alzheimer's Disease γ-Secretase Generates Higher 42:40 Ratios for β-Amyloid Than for p3 Peptides.
    Siegel G; Gerber H; Koch P; Bruestle O; Fraering PC; Rajendran L
    Cell Rep; 2017 Jun; 19(10):1967-1976. PubMed ID: 28591569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
    Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
    J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of amino-terminal variants of amyloid-β peptides by capillary isoelectric focusing immunoassay.
    Haußmann U; Jahn O; Linning P; Janßen C; Liepold T; Portelius E; Zetterberg H; Bauer C; Schuchhardt J; Knölker HJ; Klafki H; Wiltfang J
    Anal Chem; 2013 Sep; 85(17):8142-9. PubMed ID: 23889568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High performance plasma amyloid-β biomarkers for Alzheimer's disease.
    Nakamura A; Kaneko N; Villemagne VL; Kato T; Doecke J; Doré V; Fowler C; Li QX; Martins R; Rowe C; Tomita T; Matsuzaki K; Ishii K; Ishii K; Arahata Y; Iwamoto S; Ito K; Tanaka K; Masters CL; Yanagisawa K
    Nature; 2018 Feb; 554(7691):249-254. PubMed ID: 29420472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The appropriate sample-handling procedure for measuring the plasma β-amyloid level using a fully automated immunoassay.
    Ishiki K; Yamashita K; Watanabe S; Miura M; Kawahira J; Arimatsu Y; Kawasaki K; Iwanaga S; Sato T
    Sci Rep; 2024 Jun; 14(1):14266. PubMed ID: 38902510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.
    Pérez-Grijalba V; Fandos N; Canudas J; Insua D; Casabona D; Lacosta AM; Montañés M; Pesini P; Sarasa M
    J Alzheimers Dis; 2016 Sep; 54(2):751-62. PubMed ID: 27567833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.